Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABVX Abivax S.A.

休市中 06-18 16:00:00 EDT

99.15

-1.00

-1.00%

盘后100.06

+0.91+0.92%

19:47 EDT

最高101.49	最低97.83	成交量170.14万
今开100.55	昨收100.15	日振幅3.65%
总市值78.51亿	流通市值42.29亿	总股本7,919万
成交额1.69亿	换手率3.99%	流通股本4,266万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":99.15,"timestamp":1781812800000,"preClose":100.15,"halted":0,"volume":1701400,"hourTrading":{"tag":"盘后","latestPrice":100.06,"preClose":99.15,"latestTime":"19:47 EDT","volume":18969,"amount":1884635.6025,"timestamp":1781826458586,"change":0.91,"changeRate":0.009178,"amplitude":0.009783},"delay":0,"changeRate":-0.009985022466300548,"floatShares":42655700,"shares":79185160,"eps":-5.216782,"marketStatus":"休市中","change":-1,"latestTime":"06-18 16:00:00 EDT","open":100.55,"high":101.49,"low":97.83,"amount":168813214.252,"amplitude":0.036545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.216782,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":100.15,"preHourTrading":{"tag":"盘前","latestPrice":100.73,"preClose":100.15,"latestTime":"09:28 EDT","volume":21782,"amount":2192481.80394,"timestamp":1781789280148,"change":0.58,"changeRate":0.005791,"amplitude":0.040539},"postHourTrading":{"tag":"盘后","latestPrice":100.06,"preClose":99.15,"latestTime":"19:47 EDT","volume":18969,"amount":1884635.6025,"timestamp":1781826458586,"change":0.91,"changeRate":0.009178,"amplitude":0.009783},"volumeRatio":1.0452897891051895,"optionData":{"bulkOrders":[{"symbol":"ABVX","call":true,"expireDate":1782964800000,"strike":"115.0","timestamp":1781812051714,"price":9.2,"volume":3878,"amount":3567760,"type":"-"},{"symbol":"ABVX","call":true,"expireDate":1782964800000,"strike":"130.0","timestamp":1781812051715,"price":5.6,"volume":1939,"amount":1085840,"type":"+"}]},"impliedVol":1.5237,"impliedVolPercentile":0.9415},"requestUrl":"/m/hq/s/ABVX/tweets","defaultTab":"tweets","newsList":[{"id":"1194191893","title":"异动解读｜Abivax S.A.盘中上涨5.15%，三期试验安全性争议消化后股价延续技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1194191893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194191893?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:59","pubTimestamp":1781708376,"startTime":"0","endTime":"0","summary":"6月17日，Abivax S.A.盘中上涨5.15%，报102.48美元/股，成交额5767.44万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期市场反应或过度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160844250","title":"异动解读｜Abivax S.A.盘中上涨5.03%，三期试验安全性争议消化后股价延续技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1160844250","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160844250?lang=zh_cn&edition=full","pubTime":"2026-06-16 00:25","pubTimestamp":1781540736,"startTime":"0","endTime":"0","summary":"6月16日，Abivax S.A.盘中上涨5.03%，报101.41美元/股，成交额7746.5万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例引发股价自130美元附近暴跌至约70美元，跌幅一度近50%。部分投资者认为癌症病例更可能与患者年龄相关，市场前期反应或过度。当前股价自低位持续回升，反映多空博弈中买方力量阶段性占优。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126571678","title":"异动解读｜Abivax S.A.盘中下跌5.27%，三期试验癌症病例安全性争议叠加证券欺诈调查持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126571678","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126571678?lang=zh_cn&edition=full","pubTime":"2026-06-10 23:01","pubTimestamp":1781103697,"startTime":"0","endTime":"0","summary":"6月10日，Abivax S.A.盘中下跌5.27%，报97.51美元/股，成交额4363.33万美元。Wedbush Securities指出该药面临黑框警告风险上升。此外，The Schall Law Firm已对公司启动证券欺诈调查，聚焦其是否就临床试验结果发布虚假或误导性陈述。双重利空叠加下，安全性争议及法律风险持续压制市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782210","title":"异动解读｜Abivax S.A.盘中下跌5.32%，三期试验癌症病例安全性争议持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782210","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143782210?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:04","pubTimestamp":1780927474,"startTime":"0","endTime":"0","summary":"6月8日，Abivax S.A.盘中下跌5.32%，报97.13美元/股，成交额5404.34万美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例及多例非黑色素瘤皮肤癌，安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164583039","title":"异动解读｜Abivax S.A.盘中下跌5.49%，三期试验癌症病例安全性争议持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1164583039","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164583039?lang=zh_cn&edition=full","pubTime":"2026-06-05 23:19","pubTimestamp":1780672755,"startTime":"0","endTime":"0","summary":"6月5日，Abivax S.A.盘中下跌5.49%，报99.57美元/股，成交额1.28亿美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，安全性争议仍未消除。Wedbush Securities亦指出obefazimod面临黑框警告风险上升。该股此前盘中一度暴跌超40%后有所反弹，当前再度回落反映安全性隐忧仍在主导市场定价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172429889","title":"异动解读｜Abivax S.A.盘中上涨5.65%，三期试验因癌症病例引发暴跌后延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1172429889","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172429889?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:12","pubTimestamp":1780582369,"startTime":"0","endTime":"0","summary":"6月4日，Abivax S.A.盘中上涨5.65%，报98.405美元/股，成交额1.26亿美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，该股此前盘中一度暴跌超40%。当前股价延续反弹走势，反映部分资金逢低博弈，但杰富瑞分析师指出癌症相关不良事件将持续压制市场情绪及药物商业化前景，安全性争议仍未消除。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162823209","title":"异动解读｜Abivax S.A.盘中上涨16.03%，三期试验因癌症病例引发暴跌后盘中延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1162823209","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162823209?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:37","pubTimestamp":1780493835,"startTime":"0","endTime":"0","summary":"6月3日，Abivax S.A.盘中上涨16.03%，报84.875美元/股，成交额1.39亿美元。当前盘中大幅回升反映部分资金逢低博弈，但杰富瑞分析师指出癌症相关不良事件将持续压制市场情绪及药物商业化前景，安全性争议仍未消除。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175805806","title":"异动解读｜Abivax S.A.盘前上涨6.21%，三期试验因癌症病例引发暴跌后盘前延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1175805806","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175805806?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:59","pubTimestamp":1780477145,"startTime":"0","endTime":"0","summary":"6月3日，Abivax S.A.盘前上涨6.21%，报76.9美元/股，成交额413.49万美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，Wedbush Securities指出obefazimod因恶性肿瘤病例面临黑框警告风险上升。此前该股盘中一度暴跌超40%，当前盘前小幅回升反映部分资金逢低博弈，但安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132003257","title":"异动解读｜Abivax S.A.夜盘上涨5.28%，三期试验因癌症病例引发暴跌后盘后小幅回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1132003257","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132003257?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:07","pubTimestamp":1780456044,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.夜盘上涨5.28%，报76.33美元/股，成交额33.09万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，Wedbush Securities指出obefazimod因恶性肿瘤病例面临黑框警告风险上升。当前夜盘小幅回升反映部分资金逢低博弈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122300146","title":"异动解读｜Abivax S.A.盘后上涨5.12%，三期试验因癌症病例引发暴跌后盘后小幅回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1122300146","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122300146?lang=zh_cn&edition=full","pubTime":"2026-06-03 05:17","pubTimestamp":1780435057,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘后上涨5.12%，报76.33美元/股，成交额402.8万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价遭大幅抛售，盘中跌幅一度超40%，反映投资者对药物安全性风险的重新定价，盘后出现小幅回升。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165305488","title":"异动解读｜Abivax S.A.盘中下跌40.7%，三期试验数据因癌症病例复杂化引发市场恐慌","url":"https://stock-news.laohu8.com/highlight/detail?id=1165305488","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165305488?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:37","pubTimestamp":1780407466,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘中下跌40.7%，报81.915美元/股，成交额3.03亿美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价即遭大幅抛售，反映投资者对药物安全性风险的重新定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161098666","title":"异动解读｜Abivax S.A.盘前下跌30.12%，三期试验数据因癌症病例复杂化引发市场恐慌","url":"https://stock-news.laohu8.com/highlight/detail?id=1161098666","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161098666?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:06","pubTimestamp":1780387566,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘前下跌30.12%，报88.88美元/股，成交额179.2万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但有报道称试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价即遭大幅抛售，反映投资者对药物安全性风险的重新定价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168642211","title":"异动解读｜Abivax S.A.夜盘下跌25.58%，Obefazimod三期维持试验达主要终点但市场反应消极","url":"https://stock-news.laohu8.com/highlight/detail?id=1168642211","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168642211?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:02","pubTimestamp":1780358521,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.夜盘下跌25.58%，报96.51美元/股，成交额1.87万美元。消息面上，公司公布其核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到了主要终点，25mg和50mg两个剂量组亦满足相关目标，但市场对数据表现反应消极，股价在盘后大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188619399","title":"异动解读｜Abivax S.A.盘后上涨31.08%，报170.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188619399","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188619399?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:31","pubTimestamp":1780345862,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘后上涨31.08%，报170.0美元/股，成交额970.37万美元。Abivax S.A.所在的生物科技行业中，个股中，Revolution Medicines涨0.53%，艾伯维公司跌0.53%，吉利德科学持平，安进涨0.46%，再生元制药公司涨0.22%。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131761327","title":"异动解读｜Abivax S.A.盘中上涨5.03%，财报披露现金储备充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1131761327","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131761327?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:16","pubTimestamp":1779808609,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.盘中上涨5.03%，报128.12美元/股，成交额8500.7万美元。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155275439","title":"异动解读 | 现金储备充裕缓解研发担忧，Abivax S.A.盘前大涨8.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1155275439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155275439?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:14","pubTimestamp":1779783267,"startTime":"0","endTime":"0","summary":"生物技术公司Abivax S.A.（股票代码：ABVX）今日盘前股价大幅上涨8.26%，表现强劲。消息面上，公司近期披露的财务数据显示，截至3月31日，其持有的现金、现金等价物及短期投资总额达4.916亿欧元。基于当前的运营假设，公司预计其现金跑道可延续至今年第四季度。这一充裕的资金状况有效缓解了市场对其核心药物研发项目可持续性的担忧。此外，市场情绪受到机构看多观点的提振。多数卖方分析师维持对该股的买入评级，并给出了高于当前股价的目标价。市场普遍关注其融资与版税安排对长期现金流路径的积极影响，这共同构成了推动股价在盘前时段显著走高的主要因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143487991","title":"异动解读｜Abivax S.A.盘前上涨9.06%，财报披露现金储备充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1143487991","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143487991?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:07","pubTimestamp":1779782858,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.盘前上涨9.06%，报130.46美元/股，成交额122.15万美元。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199128647","title":"异动解读 | 现金储备充裕缓解研发担忧，Abivax S.A.夜盘大涨9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199128647","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199128647?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:35","pubTimestamp":1779780949,"startTime":"0","endTime":"0","summary":"Abivax S.A.（股票代码：ABVX）今日夜盘股价大幅上涨9.85%，表现强劲。消息面上，公司近期披露的财务数据显示，截至3月31日，其持有的现金、现金等价物及短期投资总额达4.916亿欧元。基于当前的运营假设，公司预计其现金跑道可延续至今年第四季度。这一充裕的资金状况有效缓解了市场对其核心药物研发项目可持续性的担忧。此外，市场情绪受到机构看多观点的提振。多数卖方分析师维持对该股的买入评级，并给出了高于当前股价的目标价。市场普遍关注其融资与版税安排对长期现金流路径的积极影响，这共同构成了推动股价在夜盘时段显著走高的主要因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132190360","title":"异动解读｜Abivax S.A.夜盘上涨5.8%，财报披露现金储备充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1132190360","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132190360?lang=zh_cn&edition=full","pubTime":"2026-05-26 08:21","pubTimestamp":1779754894,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.夜盘上涨5.8%，报129.06美元/股。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax Sa是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190413427","title":"异动解读｜Abivax S.A.盘中上涨5.09%，财报发布在即机构看多情绪占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1190413427","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190413427?lang=zh_cn&edition=full","pubTime":"2026-05-22 02:27","pubTimestamp":1779388050,"startTime":"0","endTime":"0","summary":"5月22日，Abivax S.A.盘中上涨5.09%，报125.885美元/股，成交额9558.64万美元。消息面上，Abivax S.A.将于5月25日美股盘前发布财报，尽管本季度营收预计同比锐减88.78%，但从已披露的机构观点看，看多阵营占优，多数卖方对公司维持买入评级基调，并给出高于现价区间的目标价，市场聚焦其融资与版税安排对费用及现金流路径的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":-0.0171},{"period":"1month","weight":-0.1282},{"period":"3month","weight":-0.1761},{"period":"6month","weight":-0.1374},{"period":"1year","weight":15.3884},{"period":"ytd","weight":-0.2648}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abivax Sa是一家于2013年12月4日根据法国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法。其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}